B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2008-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0022-5347(08)60301-8PMID 18042703PMCID PMC2148311
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer

  2007cited by this paper
• Implications of B7-H1 Expression in Clear Cell Carcinoma of the Kidney for Prognostication and Therapy

  2007cited by this paper
• Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.

  2007cited by this paper
• Cancer Statistics, 2007

  2007cited by this paper
• A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer

  2007cited by this paper
• B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration.

  2007cited by this paper
• Checkpoint blockade in cancer immunotherapy.

  2007cited by this paper
• Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

  2007cited by this paper
• The B7 Family and Cancer Therapy: Costimulation and Coinhibition

  2007cited by this paper
• B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy.

  2007cited by this paper
• Relationship between co-stimulatory molecule B7-H3 expression and gastric carcinoma histology and prognosis.

  2006cited by this paper
• An orthotopic colon cancer model for studying the B7-H3 antitumor effect in vivo

  2006cited by this paper
• B7-H4 expression in renal cell carcinoma and tumor vasculature: Associations with cancer progression and survival

  2006cited by this paper
• B7-H4 overexpression in ovarian tumors.

  2006cited by this paper
• Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

  2006cited by this paper
• B7-H3 and B7-H4 expression in non-small-cell lung cancer.

  2006cited by this paper
• Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

  2005cited by this paper
• B7-H4 Is Highly Expressed in Ductal and Lobular Breast Cancer

  2005cited by this paper
• The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation.

  2005cited by this paper
• Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity

  2004cited by this paper
• Murine B7-H3 Is a Negative Regulator of T Cells1

  2004cited by this paper
• Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis.

  2004cited by this paper
• Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.

  2004cited by this paper
• B7-H3 Enhances Tumor Immunity In Vivo by Costimulating Rapid Clonal Expansion of Antigen-Specific CD8+ Cytolytic T Cells1

  2004cited by this paper
• B7x: A widely expressed B7 family member that inhibits T cell activation

  2003cited by this paper
• Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

  2003cited by this paper
• Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

  2003cited by this paper
• Genomic Organization and Expression Analysis of B7-H4, an Immune Inhibitory Molecule of the B7 Family 1

  2003cited by this paper
• B7-H4, a molecule of the B7 family, negatively regulates T cell immunity.

  2003cited by this paper
• B7S1, a novel B7 family member that negatively regulates T cell activation.

  2003cited by this paper
• Mouse B7-H3 induces antitumor immunity

  2003cited by this paper
• The B7 family member B7-H3 preferentially down-regulates T helper type 1–mediated immune responses

  2003cited by this paper
• B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production.

  2001cited by this paper
• CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.

  2001cited by this paper
• Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?

  2001cited by this paper
• What do we mean by validating a prognostic model?

  2000cited by this paper
• B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

  1999cited by this paper
• Enhancement of Antitumor Immunity by CTLA-4 Blockade

  1996cited by this paper
• Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells.

  1993cited by this paper

• CD276 immature glycosylation drives colorectal cancer aggressiveness and T cell mediated immune escape

  2026cites this paper
• Palmitic acid-triggered B7H3 palmitoylation promotes immune escape

  2026cites this paper
• Single-cell RNA sequence analysis reveals USP32 as a therapeutic target to mitigate PD-L1-driven colorectal tumorigenesis in vitro and in vivo

  2026cites this paper
• sB7-H3 as a prognostic biomarker in osteosarcoma: insights into clinical outcomes.

  2026cites this paper
• B7-H3: a consistent marker in metastatic colorectal cancer with potential for targeted treatment

  2025cites this paper
• A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3–Expressing Relapsed or Refractory Solid Tumors

  2025cites this paper
• Systematic profiling of tumor-associated antigen expression for antibody-drug conjugate in prostate cancer.

  2025cites this paper
• PARP inhibitors accumulate B7-H3 on fibroblasts via blocking autophagic flux to potentiate immune evasion in ovarian cancer

  2025cites this paper
• B7-H3 in the tumor microenvironment: Implications for CAR T cell therapy in pediatric solid tumors

  2025cites this paper
• Predictive Significance of CD276/B7-H3 Expression in Baseline Biopsies of Advanced Prostate Carcinoma

  2025cites this paper
• Prognostic Significance of B7H3 Expression in Solid Tumors: A Systematic Review and Meta-Analysis

  2025cites this paper
• Exploring B7-H4's role in prostate cancer dormancy post-androgen deprivation therapy: extracellular matrix interactions and therapeutic opportunities.

  2025cites this paper
• Design and Preclinical Validation of an Anti-B7-H3-Specific Radiotracer: A Non-Invasive Imaging Tool to Guide B7-H3-Targeted Therapies

  2025cites this paper
• B7-H4 ImmunoPET Imaging Tracks Tumor-Associated Macrophage Changes in Prostate Cancer.

  2025cites this paper
• A novel cancer-associated lncRNA, LINC01123, participates in tumor progression, metabolism, immune escape, and resistance

  2025cites this paper
• T cell-engaging CD276xCD3 bispecific antibody for treatment of endometrial cancer

  2025cites this paper
• Fc-optimized CD276 antibody enhances NK cell activation against non-small cell lung cancer

  2025cites this paper
• The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer

  2025cites this paper
• Comparison of approaches for increasing affinity of affibody molecules for imaging of B7-H3: dimerization and affinity maturation

  2024cites this paper
• B7-H3 suppresses CD8+ T cell immunologic function through reprogramming glycolytic metabolism

  2024cites this paper
• CD276 Promotes an Inhibitory Tumor Microenvironment in Hepatocellular Carcinoma and is Associated with Poor Prognosis

  2024cites this paper
• A Pan-Cancer Analysis of the Oncogenic Role of CD276 in Human Tumors

  2024cites this paper
• Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody

  2024cites this paper
• New Emerging Targets in Cancer Immunotherapy: The Role of B7-H3

  2024cites this paper
• Clinical significance of blocking novel immune checkpoint B7-H4 in urothelial carcinoma of bladder as a potential therapeutic target

  2024cites this paper
• DAMPening Tumor Immune Escape: The Role of Endoplasmic Reticulum Chaperones in Immunogenic Chemotherapy

  2024cites this paper
• Prognostic Value of B7H4 Expression in Patients with Solid Cancers: A Systematic Review and Meta-Analysis

  2024cites this paper
• Statins inhibit onco-dimerization of the 4Ig isoform of B7-H3

  2024cites this paper
• An Fc-modified monoclonal antibody as novel treatment option for pancreatic cancer

  2024cites this paper
• In vivo imaging of T-cell coregulator B7-H4 reveals protumor macrophage status in prostate cancer

  2024cites this paper
• A promising target for breast cancer: B7-H3

  2024cites this paper
• The immune regulatory function of B7-H3 in malignancy: spotlight on the IFN-STAT1 axis and regulation of tumor-associated macrophages

  2024cites this paper
• Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities

  2024cites this paper
• B7-H3 in glioblastoma and beyond: significance and therapeutic strategies

  2024cites this paper
• Immuno-oncologic profiling by stage-dependent transcriptome and proteome analyses of spontaneously regressing canine cutaneous histiocytoma

  2024cites this paper
• High dimensional analyses reveal IL-15 enhances activation of Sipuleucel-T lymphocyte subsets and reverses immunoresistance.

  2024cites this paper
• The Immune Microenvironment in Prostate Cancer: A Comprehensive Review

  2024cites this paper
• Spatial whole transcriptome profiling of primary tumor from patients with metastatic prostate cancer

  2023cites this paper
• Evaluation of affinity matured Affibody molecules for imaging of the immune checkpoint protein B7-H3.

  2023cites this paper
• B7-H3 and CD47 co-expression in gastric cancer is a predictor of poor prognosis and potential targets for future dual-targeting immunotherapy

  2023cites this paper
• Targeting Histone 3 Variants Epigenetic Landscape and Inhibitory Immune Checkpoints: An Option for Paediatric Brain Tumours Therapy

  2023cites this paper
• IL-15 enhances anti-tumor immunity of sipuleucel-T by activating lymphocyte subsets and reversing immunoresistance

  2023cites this paper
• Unlocking molecular mechanisms and identifying druggable targets in matched-paired brain metastasis of breast and lung cancers

  2023cites this paper
• Synthesis and Evaluation of Clinically Translatable Targeted Microbubbles Using a Microfluidic Device for In Vivo Ultrasound Molecular Imaging

  2023cites this paper
• Development of a MMAE-based antibody-drug conjugate targeting B7-H3 for glioblastoma.

  2023cites this paper
• Immune Profiling of Meningiomas.

  2023cites this paper
• Heterogeneous Expression of PD-L1, B7x, B7-H3, and HHLA2 in Pulmonary Sarcomatoid Carcinoma and the Related Regulatory Signaling Pathways

  2023cites this paper
• B7-H3 immunoregulatory roles in cancer.

  2023cites this paper
• The loss of B7-H4 expression in breast cancer cells escaping from T cell cytotoxicity contributes to epithelial-to-mesenchymal transition

  2023cites this paper
• Membrane tension-mediated stiff and soft tumor subtypes closely associated with prognosis for prostate cancer patients

  2023cites this paper
• Tumor-derived biomarkers beyond antigen expression enhance efficacy of CD276/B7H3 antibody-drug conjugate in metastatic prostate cancer

  2023cites this paper
• Comprehensive characterization of B7 family members in NSCLC and identification of its regulatory network

  2023cites this paper
• B7x in cancer immunity and immunotherapy.

  2023cites this paper
• IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer

  2023cites this paper
• Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models

  2023cites this paper
• Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma

  2023cites this paper
• Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies

  2023cites this paper
• A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC

  2023cites this paper
• Influence of ADT on B7-H3 expression during CRPC progression from hormone-naïve prostate cancer

  2023cites this paper
• B7-H3 as a therapeutic target in advanced prostate cancer

  2022cites this paper
• The evolving role of checkpoint inhibitors in the treatment of urothelial carcinoma

  2022cites this paper
• To kill a cancer: Targeting the immune inhibitory checkpoint molecule, B7-H3.

  2022cites this paper
• Evaluation of an Affibody-Based Binder for Imaging of Immune Check-Point Molecule B7-H3

  2022cites this paper
• B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma

  2022cites this paper
• Targeted Therapy of B7 Family Checkpoints as an Innovative Approach to Overcome Cancer Therapy Resistance: A Review from Chemotherapy to Immunotherapy

  2022cites this paper
• Comprehensive pan-cancer analysis identifies cellular senescence as a new therapeutic target for cancer: multi-omics analysis and single-cell sequencing validation.

  2022cites this paper
• The immune checkpoint B7x expands tumor-infiltrating Tregs and promotes resistance to anti-CTLA-4 therapy

  2022cites this paper
• Framework of Intrinsic Immune Landscape of Dormant Prostate Cancer

  2022cites this paper
• A Novel Anti-B7-H3 × Anti-CD3 Bispecific Antibody with Potent Antitumor Activity

  2022cites this paper
• DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody–Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models

  2022cites this paper
• Costimulatory and coinhibitory molecules of B7-CD28 family in cardiovascular atherosclerosis: A review

  2022cites this paper
• Evaluation of serum B7‐H3 expression, ultrasound and clinical characteristics to predict the risk of cervical lymph node metastases in papillary thyroid carcinoma by nomogram

  2022cites this paper
• Association of B7‐H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer

  2022cites this paper
• V-set domain containing T-cell activation inhibitor-1 (VTCN1): A potential target for the treatment of autoimmune diseases.

  2022cites this paper
• Suppressive function of bone marrow-derived mesenchymal stem cell-derived exosomal microRNA-187 in prostate cancer

  2022cites this paper
• Advances in adoptive cellular therapy for colorectal cancer: a narrative review

  2022cites this paper
• OTT_A_318082 4275..4283

  2021cites this paper
• Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling

  2021cites this paper
• The Regulatory Cross-Talk between microRNAs and Novel Members of the B7 Family in Human Diseases: A Scoping Review

  2021cites this paper
• The Role of CD276 in Cancers

  2021cites this paper
• PBK phosphorylates MSL1 to elicit epigenetic modulation of CD276 in nasopharyngeal carcinoma

  2021cites this paper
• B7-H4 induces epithelial-mesenchymal transition and promotes colorectal cancer stemness.

  2021cites this paper
• B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8+ tumor-infiltrating lymphocytes

  2021cites this paper
• B7 immune-checkpoints as targets for the treatment of neuroendocrine tumors.

  2021cites this paper
• Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer

  2021cites this paper
• Экспрессия контрольной точки иммунитета B7-H3 ее растворимой формы в сыворотке крови больных новообразованиями костей

  2021cites this paper
• A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3–Specific CAR T Cells in Solid Tumors

  2021cites this paper
• An Inflammatory Response Related Gene Signature Associated with Survival Outcome and Gemcitabine Response in Patients with Pancreatic Ductal Adenocarcinoma

  2021cites this paper
• Immune Profiling of Medullary Thyroid Cancer—An Opportunity for Immunotherapy

  2021cites this paper
• Expression of B7 family checkpoint proteins in cervical cancer

  2021cites this paper
• Integrated analysis reveals distinct molecular, clinical, and immunological features of B7‐H3 in acute myeloid leukemia

  2021cites this paper
• B7-H4 expression is upregulated by PKCδ activation and contributes to PKCδ-induced cell motility in colorectal cancer

  2021cites this paper
• Expression of B7-H3 Correlates with PD-L1 and Poor Prognosis in Patients with Cervical Cancer

  2021cites this paper
• Immune checkpoint B7‐H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer

  2021cites this paper
• B7-H3 suppresses doxorubicin-induced senescence-like growth arrest in colorectal cancer through the AKT/TM4SF1/SIRT1 pathway

  2021cites this paper
• Advances in immunotherapeutic targets for childhood cancers: a focus on glypican-2 and B7-H3.

  2021cites this paper
• Targeting CD276 by CAR-T cells induces regression of esophagus squamous cell carcinoma in xenograft mouse models

  2021cites this paper
• B7 score and T cell infiltration stratify immune status in prostate cancer

  2021cites this paper
• Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling

  2021cites this paper
• MiR-29c downregulates tumor-expressed B7-H3 to mediate the antitumor NK-cell functions in ovarian cancer.

  2021cites this paper